

# Sleep Abnormalities During Abstinence in Alcohol-Dependent Patients

## Aetiology and Management

*Hans-Peter Landolt and J. Christian Gillin*

Department of Psychiatry, University of California at San Diego, Veterans Affairs San Diego  
Healthcare System, San Diego, California, USA

### Contents

Abstract	413
1. Sleep Stages and the Sleep Electroencephalogram (EEG) in Healthy Individuals	414
2. Effect of Alcohol on Sleep and the Sleep EEG	415
2.1 Healthy Individuals	415
2.1.1 Sleep-Related Breathing and Periodic Leg Movements	416
2.2 Alcohol-Dependent Patients	417
2.2.1 Alcohol Withdrawal	417
2.2.2 Abstinence	418
3. Mechanism of Action of Alcohol	418
4. Treatment of Alcohol-Induced Sleep Disturbances	419
4.1 Pharmacological Treatment	420
4.1.1 GABAergic Agents	420
4.1.2 Serotonergic Agents	420
4.1.3 Other Medications	421
4.2 Nonpharmacological and Alternative Treatments	421
5. Conclusions	422

### Abstract

Virtually every type of sleep problem occurs in alcohol-dependent patients. Typically, these individuals take a longer time to fall asleep and show decreased sleep efficiency, shorter sleep duration and reduced amounts of slow wave sleep when compared with healthy controls. Their sleep patterns are fragmented, and the typical time course of electroencephalogram (EEG) delta wave activity is severely disrupted. The amount of rapid eye movement (REM) sleep may be reduced or increased. Sleep changes can persist during months or years of abstinence, and recent studies indicate that certain alterations in sleep architecture, as well as subjective sleep complaints, predict relapse to alcoholism.

The mechanisms of action of short and long term alcohol administration on sleep are incompletely understood. They may arise from an interaction with  $\gamma$ -aminobutyric acid (GABA), serotonin (5-hydroxytryptamine; 5-HT), adenosine or other neurotransmitter systems.

While only a few pharmacological and nonpharmacological strategies to im-

prove or normalise disturbed sleep in individuals who have recovered from alcoholism have been studied, the use of benzodiazepines, other hypnotosedatives or selective serotonin reuptake inhibitors is not recommended. Therapies include sleep hygiene, bright light therapy, meditation, relaxation methods, and other nonpharmacological approaches.

Further studies are needed to clarify the relationship between sleep, sleep abnormalities and alcoholism, and to establish new approaches to improve sleep in alcohol-dependent patients and to prevent withdrawal reactions that affect sleep during abstinence.

Severe sleep disturbances are common in alcohol-dependent patients. Virtually every type of sleep disorder – insomnia, hypersomnia, circadian rhythm sleep disorders (e.g. phase advance or phase delay of sleep period) and parasomnias (e.g. nightmares, sleep walking, enuresis) – may occur in alcohol-dependent patients during periods of drinking, withdrawal and abstinence (see Gillin and Drummond<sup>[1]</sup> for recent review).

Sleep disturbances play an important role in the diagnosis and treatment of alcoholism, and accumulating evidence suggests that objective and subjective alterations of sleep during abstinence may predict relapse in the future. Specifically, prolonged sleep latency, enhanced propensity for rapid eye movement (REM) sleep, low amounts of deep non-REM sleep and reduced sleep efficiency at different stages of abstinence are among the best predictors of treatment outcome in alcohol-dependent patients.<sup>[2-5]</sup> Moreover, patients complaining of abnormal sleep with difficulties in falling asleep are more likely to relapse than those with better subjective sleep quality.<sup>[2,6]</sup> Some alcohol-dependent individuals may resume drinking in an attempt to self-medicate their sleep problems.<sup>[7,8]</sup> The normalisation and subjective improvement of sleep during abstinence might, therefore, prevent resumption of drinking in at least this subset of patients.

Unfortunately, the aetiology and treatment of alcohol-related sleep disturbances are not well understood, and there are no widely accepted therapeutic guidelines.<sup>[9,10]</sup> In this article, we aim to provide an overview of possible interventions to improve sleep in patients recovering from alcoholism. We first describe the salient features of normal

sleep architecture and the sleep electroencephalogram (EEG). We then summarise the effects of alcohol on sleep variables, the sleep EEG, sleep-related breathing and periodic leg movements during sleep in healthy individuals and in alcohol-dependent patients. Next, we discuss the effects of alcohol on neurochemical systems which are thought to play a role in the regulation of sleep. And, finally, we outline currently available pharmacological and nonpharmacological treatment options to improve disturbed sleep in abstinent alcohol-dependent individuals.

## 1. Sleep Stages and the Sleep Electroencephalogram (EEG) in Healthy Individuals

Characteristic changes in brain electrical activity, i.e. the EEG, serve to discriminate between wakefulness and sleep. The typical  $\approx 10$  Hz alpha rhythm of quiet wakefulness changes to a pattern of theta frequencies ( $\approx 5$  to 8 Hz) during the onset of sleep (stage 1; fig. 1). Deeper sleep is characterised by the occurrence of phasic events such as sleep spindles ( $\approx 11$  to 15 Hz, sigma frequency range) and K-complexes (large regular potentials), as well as the presence of high amplitude slow waves with a frequency of  $\approx 0.5$  to 2 Hz (delta frequency range). Standardised criteria are applied to subdivide polysomnographic recordings of EEG, electro-oculogram (EOG) and electromyogram (EMG) into wakefulness, REM sleep and non-REM sleep.<sup>[11]</sup> Based on the preponderance of slow waves, non-REM sleep is further subdivided into stages 2 to 4. Undisturbed sleep in healthy adults consists of four or more consecutive non-REM/REM sleep cycles

with a periodicity of approximately 60 to 100 minutes.<sup>[12]</sup>

Computer-aided decomposition of the sleep EEG reveals functionally distinct components. Slow wave activity (SWA; spectral power within 0.75 to 4.5Hz) is thought to represent a physiological marker of non-REM sleep intensity.<sup>[13,14]</sup> After sleep onset, SWA builds up rapidly in the first non-REM sleep episode and reaches a plateau during stage 4 (fig. 1). Shortly before REM sleep, it declines sharply and remains low until it increases again in the second non-REM sleep period, where it normally reaches a lower plateau value than in the first non-REM sleep episode. The global declining trend of SWA across consecutive non-REM sleep episodes reflects the sleep-wake dependent or homeostatic facet of sleep regulation.<sup>[14-16]</sup> Accordingly, SWA is enhanced after sleep deprivation and reduced after a daytime nap.<sup>[13,17]</sup>


In addition to SWA, EEG power in the frequency range of sleep spindles also underlies homeostatic influences. However, spindle frequency activity (SFA; spectral power within 12 to 15Hz) does not decline in the course of a nocturnal sleep episode, yet is reduced after sleep deprivation.<sup>[13,18,19]</sup> It shows a complex relationship to SWA and under-

goes a characteristic modulation over the non-REM/REM sleep cycles. Highest values are seen at the onset and termination of non-REM sleep episodes, whereas the lowest values occur in REM sleep (fig. 1).

## 2. Effect of Alcohol on Sleep and the Sleep EEG

### 2.1 Healthy Individuals

It has long been known that alcohol, when given to healthy volunteers at bedtime, tends to shorten sleep latency, reduce the amount of REM sleep and prolong the duration of non-REM sleep.<sup>[20-25]</sup> Because alcohol is metabolised rapidly,<sup>[23,26,27]</sup> these changes in sleep architecture are typically confined to the first half of the night, and nocturnal withdrawal effects may disturb sleep towards the end of the sleep episode.<sup>[22,25]</sup> Specifically, late sleep may be shallow and interrupted by frequent awakenings, the amount of REM sleep may be increased, and dream recall or nightmares may be frequent. Moreover, activation of the sympathetic nervous system may induce tachycardia and sweating,<sup>[23]</sup> and gastric irritation, headache or a full



**Fig. 1.** Sleep stages and electroencephalogram (EEG) slow wave activity (SWA; power within 0.75 to 4.5Hz; grey bars) and spindle frequency activity (SFA; power within 12.25 to 15Hz; blue line) during an 8-hour sleep episode in a young healthy man. 20-second epochs of W and MT were excluded for calculation of SWA and SFA. The calibration mark at the right of the x-axis represents 300  $\mu\text{V}^2/\text{Hz}$  of SWA and 10  $\mu\text{V}^2/\text{Hz}$  of SFA, respectively. Roman numerals at the top of the figure indicate consecutive non-REM/REM sleep cycles. 1, 2, 3, 4 = non-rapid eye movement (REM) sleep stages; MT = movement time; R = REM sleep; W = waking.

bladder may occur, all of which cause repeated sleep interruptions.

While alcohol is commonly used by individuals with sleep disorders in an attempt to self-medicate, it can be seen that this is not appropriate and in fact counterproductive. Indeed, the International Classification of Sleep Disorders (ICSD) lists 'alcohol-dependent sleep disorder',<sup>[28]</sup> which occurs typically in patients with insomnia who do not have a diagnosis of alcoholism and who use alcohol as a bedtime sleeping aid for >30 days. Characteristic symptoms include restlessness and nocturnal awakenings with sweating, headache, dreams and dry mouth.<sup>[1]</sup>

The alcohol concentration in plasma may reach higher levels in older people than in young adults, especially in men,<sup>[29,30]</sup> and in these individuals sleep after alcohol consumption may be most strongly affected. For example, the consumption of 0.55 g/kg bodyweight of alcohol in the late afternoon (at 1700h) produced a maximum breath alcohol concentration of  $\approx 0.9$  mg/L in 10 healthy late middle-aged men (mean age of 62 years).<sup>[27]</sup> Breath alcohol levels were zero at the beginning of the sleep episode at 2300h. Nevertheless, individuals perceived their sleep as more superficial when compared with a control situation (i.e. consumption of mineral water). Sleep efficiency, total sleep time and the duration of REM sleep and stage 1 were decreased. In the second half of the night, wakefulness was doubled. These data demonstrate that early evening alcohol consumption can disrupt sleep in men who are not alcohol-dependent at a time when the breath alcohol concentration has fallen to undetectable levels.

In the same study, EEG power densities in low delta frequencies were enhanced in non-REM sleep and REM sleep after alcohol consumption when compared with the control situation.<sup>[27]</sup> The most prominent changes occurred in slow wave sleep (SWS, stages 3 and 4), in which activity was increased in the delta, alpha and sigma bands. While these sleep EEG effects demonstrate a central action of alcohol at a time when the substance

can no longer be detected, their physiological significance remains to be established.

In an earlier study involving 8 young adults, alcohol-induced changes during sleep were found to persist for longer than 24 hours.<sup>[31]</sup> The changes consisted of enhanced EEG power within the delta and alpha bands in SWS and were very similar to those in the older men after late afternoon alcohol consumption.

Furthermore, alcohol intake in the morning was reported to lead to sedation and impaired performance in divided attention and simulated automobile driving tasks in the afternoon, at a time when the alcohol concentration in breath in 12 healthy young men was approaching zero.<sup>[32]</sup> Interestingly, performance impairment appeared to be more pronounced after partial sleep deprivation (4 hours) than after a normal night of sleep (8 hours). These results suggest that the sedative effects of alcohol may arise from an 'unmasking' of a previously present sleep deficit. This finding is especially relevant for individuals with a high level of sleepiness (e.g. patients with sleep disorders or sleep apnoea, shift workers, or people with jet lag) in whom the impairing effect of alcohol may be enhanced, and the risk for alcohol-related automobile accidents may be increased.

### **2.1.1 Sleep-Related Breathing and Periodic Leg Movements**

Superficial, shallow, nonrefreshing sleep with frequent arousals may be caused by disturbances of breathing and motor control during sleep.<sup>[28]</sup> For example, sleep apnoea or hypopnoea (repeated cessation or significant reduction of breathing for more than 10 seconds), restless legs syndrome (RLS) and periodic limb movements of sleep (PLMS) may prevent sleep or arouse an individual from sleep.

In 10 non-obese healthy men with no history of snoring or disturbed sleep-related breathing, alcohol enhanced snoring and upper airway resistance during sleep.<sup>[33]</sup> This may be related to an alcohol-induced selective inhibition of upper airway motor activity and concomitant increase in total inspiratory resistance.

A higher prevalence of sleep apnoea and/or hypopnoea than in controls ( $n = 20$ ) has been observed in individuals with chronic alcoholism ( $n = 24$ ) despite 3 to 6 weeks of abstinence.<sup>[34]</sup> Additionally, in a large sample of 643 men and 341 women attending a general sleep disorders centre, the likelihood of having PLMS was significantly higher in patients who consumed 2 or more alcoholic drinks per day than in those who did not.<sup>[35]</sup>

These detrimental effects of alcohol on sleep-related breathing and PLMS may cause excessive daytime sleepiness and fatigue during the day in otherwise healthy individuals or persons with mild upper airway restriction or pre-existing sleep apnoea or PLMS.

## 2.2 Alcohol-Dependent Patients

As alcoholism develops, patients often report that they are unable to sleep without a drink. Long term ingestion of alcohol, however, typically leads to a loss of SWS and SWA, and disruption and fragmentation of sleep patterns. When compared with age- and gender-matched controls in polysomnographic studies, alcohol-dependent patients showed prolonged sleep latency, decreased sleep efficiency, shorter sleep duration, reduced amount of SWS, and increased percentage of REM sleep.<sup>[36]</sup> In some patients, the normal rest-activity cycle may be disrupted. They can develop so-called 'polyphasic sleep-wake behaviour' with short, alcohol-induced periods of sleep and short periods of wakefulness (especially with binge drinking).<sup>[37]</sup>

According to their belief that alcohol improves sleep, some alcohol-dependent patients may continue drinking or resume drinking after abstinence in an attempt to avoid insomnia.<sup>[8]</sup> Few studies have examined the effect of acute alcohol intake on the sleep of alcohol-dependent individuals while they are actually drinking. Early studies suggested that alcohol promotes SWS initially.<sup>[38]</sup> Repeated use, however, may lead to rapid tolerance to this effect.

### 2.2.1 Alcohol Withdrawal

The severity of sleep disturbances during alcohol withdrawal varies, probably with the degree of

physical dependence, as well as factors such as general health, nutritional status, past history of alcoholism and delirium tremens (DTs). In less severe withdrawal, unmedicated patients may experience symptoms of hyperarousal and jitteriness, and 3 to 5 days of altered sleep patterns with fragmented, shallow, short sleep episodes, often with increased amounts of REM sleep.<sup>[37,39-41]</sup> Since alcohol, particularly in large quantities, may suppress REM sleep, the elevated amounts of REM sleep during withdrawal may be viewed as a 'REM sleep rebound'. During DTs, sleep duration can be dramatically curtailed and fragmented, and REM sleep may be increased. Some patients may experience prolonged periods of sleep, so-called 'terminal sleep', while coming out of an episode of DTs.<sup>[42,43]</sup>

By the end of 1 to 2 weeks of abstinence, most patients show a slow improvement in sleep latency, sleep efficiency and total sleep time, and reduced wake time after sleep onset (WASO).<sup>[39-41,44]</sup> Nevertheless, at an average of 17 days post-abstinence, sleep efficiency, total sleep time and SWS were significantly reduced in 31 relatively healthy, 'pure' primarily alcohol-dependent individuals (i.e. without comorbid diagnoses such as depression) compared with those in 34 controls.<sup>[45]</sup> Sleep latency and REM density (a measure of ocular activity during REM sleep) were increased. While stage 4 sleep declines with age in both healthy controls and alcohol-dependent individuals, the decline was premature in the patients. i.e. young alcohol-dependent individuals showed sleep patterns similar to those of much older normal controls.

### Depression and Sleep Disturbances

During the first weeks of withdrawal, many alcohol-dependent individuals experience depressed mood, and a sizeable number, perhaps 15 to 25% in an inpatient alcohol treatment ward, meet diagnostic criteria of a major depressive episode.<sup>[46]</sup> Fortunately, this episode usually abates within a few weeks without specific antidepressant therapy.<sup>[46]</sup> Many of these depressed patients have never had a prior episode of depression in the absence of drinking. Patients who first experience a major depres-

sive episode during withdrawal have been described as having 'secondary depression'.<sup>[47-49]</sup>

Alcohol-dependent patients who have secondary depression share many of the polygraphic sleep abnormalities traditionally associated with a primary major depressive disorder.<sup>[36]</sup> In addition to the subjective complaints of insomnia, they frequently show short REM sleep latency, decreased SWS, sleep efficiency and total sleep time, and increased WASO and REM density during the first month of withdrawal compared with nondepressed alcohol-dependent individuals and healthy controls.<sup>[45,50,51]</sup> Furthermore, although alcohol-dependent individuals with secondary depression are not usually as severely depressed as individuals with primary depression, as measured with the Hamilton Rating Scale of Depression, their objective sleep changes are often as prominent as, if not more so.<sup>[50,51]</sup> For instance, the percentage of REM sleep can be higher and SWS lower in depression secondary to alcoholism than in primary depression.

### 2.2.2 Abstinence

Abnormal sleep patterns in alcohol-dependent patients persist for months to years during recovery and abstinence. Even 1 to 2 years after drinking has stopped, sleep tends to be short and fragmented. Thus, total sleep time of 9 abstinent patients was just barely within normal age-matched limits at 14 months of sobriety.<sup>[5]</sup> Moreover, the percentage of sleep spent in SWS, as well as REM sleep latency, were still low after more than 1 year of abstinence. In 4 patients who were studied after an average of 27 months of abstinence, REM sleep percentage remained elevated and REM sleep latency short compared with healthy controls. These recent findings corroborate earlier observations by Williams and Rundell,<sup>[52]</sup> who reported objective sleep abnormalities after about 2 years of abstinence.

## 3. Mechanism of Action of Alcohol

Alcohol has long been thought to exert its pharmacological actions via an unspecific increase in the lipid fluidity of neuronal membranes ('the lipid theory of alcohol action'). Recent evidence, however, suggests that the substance can selec-

tively modulate neurochemical processes in discrete regions of the CNS.<sup>[53,54]</sup> Its effects on sleep may arise from an interaction with lipophilic domains of  $\gamma$ -aminobutyric acid (GABA), serotonin (5-hydroxytryptamine; 5-HT), adenosine, glutamate, acetylcholine or glycine receptors.<sup>[54]</sup> Some of these neurotransmitters and neuromodulators may play important roles in the regulation of vigilance and sleep.<sup>[55-63]</sup>

To gain better insights into the neurochemical mechanisms underlying the effects of alcohol on sleep, these effects can be compared to the effects of compounds which have a known mechanism of action and affect these neurotransmitter systems selectively. For example, benzodiazepines (BDZs) and their analogues are thought to influence sleep and the sleep EEG by potentiating the inhibitory action of GABA at GABA<sub>A</sub> receptors.<sup>[61,62]</sup> Similar to alcohol, BDZs promote the onset of sleep, increase the duration of non-REM sleep and, at high doses, reduce the amount of REM sleep. They cause characteristic changes in the sleep EEG, which include the reduction of power in delta and theta frequencies and the promotion of sleep spindles. These distinct EEG changes have been referred to as the 'spectral GABA-BDZ signature'.<sup>[64]</sup>

Partially similar effects have been reported after melatonin administration before a daytime nap, at a time of day when endogenous melatonin levels are low.<sup>[65]</sup> These findings are in accordance with data in rats, which indicate that melatonin may enhance GABAergic activity at GABA<sub>A</sub> receptors.<sup>[66]</sup> Alcohol may or may not potentiate GABAergic neurotransmission.<sup>[54]</sup> Because alcohol increases delta frequencies in non-REM and REM sleep,<sup>[27,31]</sup> it appears unlikely that its effects on sleep are mediated by agonistic modulation of GABA<sub>A</sub> receptors.

Recent studies have shown that in contrast to the BDZs and analogues, structural GABA agonists such as muscimol and 4,5,6,7-tetrahydroisoxazolo-[4,5-c]pyridin-3-ol (THIP) and the GABA uptake inhibitor tiagabine increase SWS and SWA and reduce power in the frequency range of sleep spindles.<sup>[67-69]</sup> These effects resemble those of alcohol

more closely than those of the BDZs. Moreover, they are very similar to those of other compounds which inhibit serotonergic neurotransmission. Specifically, like alcohol,<sup>[27,31]</sup> single doses of THIP,<sup>[68]</sup> the 5-HT<sub>1A</sub> receptor agonist ipsapirone (which probably leads to decreased neuronal activity at serotonin 5-HT<sub>2</sub> receptors),<sup>[70]</sup> and the 5-HT<sub>2</sub> receptor antagonists seganserin<sup>[71]</sup> and SR 46349B<sup>[72]</sup> enhance low delta frequency activity in non-REM sleep. These findings are in accordance with *in vitro* studies indicating that low concentrations of alcohol potentiate muscimol- and GABA-stimulated GABA<sub>A</sub> receptor function in isolated cortical membranes and cell preparations of rats and mice.<sup>[73,74]</sup> In addition, alcohol inhibits a serotonin-activated chloride current in 5-HT<sub>2A</sub> receptors.<sup>[75]</sup>

The similar sleep EEG changes induced by alcohol, tonic GABA<sub>A</sub> receptor activation and 5-HT<sub>2</sub> receptor inhibition may reflect a common effect on sleep EEG power spectra. In this context it is interesting to note that recent studies in cats indicate that serotonergic cells of dorsal raphe nuclei may be under the tonic inhibitory influence of GABAergic neurons throughout the sleep-wake cycle.<sup>[76]</sup>

Pharmacological stimulation of adenosine receptors in rats is followed by enhanced delta frequency activity in non-REM sleep and suppression of REM sleep.<sup>[77,78]</sup> These effects resemble the initial effects of alcohol and are in accordance with the notion that alcohol inhibits uptake of extracellular adenosine from the interstitial space.<sup>[79,80]</sup> In contrast, low doses of the adenosine receptor antagonist caffeine prolong sleep latency, reduce low delta EEG frequencies, and enhance power in the frequency range of sleep spindles.<sup>[81,82]</sup> These changes may be similar to the alcohol-induced changes in later parts of the night.<sup>[27]</sup> Taken together these data indicate that alcohol may affect sleep and the sleep EEG via adenosinergic mechanisms. Nevertheless, the potency of alcohol to inhibit adenosine transport in hippocampal brain slices is low,<sup>[83]</sup> and its effects on intermittent wakefulness after sleep onset differ from those of caffeine.<sup>[27,81,82]</sup>

Apart from the classical neurotransmitters and their receptors, the growth factor and cytokine systems in the brain may be prominently involved in the physiological regulation of sleep.<sup>[55,84]</sup> For example, a highly reproducible pulse of growth hormone (GH) secretion occurs with SWS, indicating that GH-releasing hormone (GHRH) may be involved in the control of these processes.<sup>[85]</sup> Moreover, the GABA metabolite  $\gamma$ -hydroxy butyrate (GHB) and the 5-HT<sub>2</sub> receptor antagonist ritanserin induce a simultaneous enhancement of GH secretion and SWS and SWA during the initial hours of sleep.<sup>[86,87]</sup> In contrast, short and long term alcohol intake in individuals who are not alcohol-dependent produces a prominent reduction in the nocturnal SWS-related GH pulse.<sup>[88]</sup> Moreover, insulin-induced release of GH during wakefulness remained below control values for several days of abstinence in alcohol-dependent patients.<sup>[89]</sup>

#### 4. Treatment of Alcohol-Induced Sleep Disturbances

Persistent sleep disturbances such as delayed sleep onset, frequent awakenings and reduced amounts of SWS during abstinence are among the difficulties that may challenge the successful treatment of alcoholism.<sup>[45,90]</sup> Recent data indicate that an increased propensity for REM sleep, prolonged sleep latency, reduced sleep efficiency, and subjective sleep complaints at different stages of sobriety can predict early relapse to drinking (see Gillin and Drummond<sup>[1]</sup> for review). The attempt to normalise alcohol-related sleep changes may, therefore, improve therapeutic outcome in some patients.

Sleep disturbances following alcohol dependence may reflect symptoms of central neuroadaptation or neurodegeneration, and successful treatment of alcoholism should reverse these changes and improve sleep persistently. For example, long-lasting alterations in GABAergic, adenosinergic, glutamatergic, dopaminergic and serotonergic neurotransmitter function have been implicated in withdrawal symptoms and relapse in alcohol-dependent patients and in animal models of alcohol dependence.<sup>[91-98]</sup> Treatment to normalise these neuro-

transmitter systems may be expected to improve sleep in the long term and prevent relapse in recovering patients.

In the US, the aldehyde dehydrogenase-blocker disulfiram and the opioid receptor antagonist naltrexone are the only medications approved by the Food and Drug Administration (FDA) to treat alcohol dependence. In Europe, acamprosate, an amino acid derivative that may normalise glutamatergic and GABAergic neurotransmission, is also in clinical use.<sup>[99,100]</sup> Whereas a small reduction of REM sleep was observed in an early study with disulfiram,<sup>[101]</sup> the effects of the other 2 agents on sleep in abstinent patients are unknown.

Unfortunately, only a few pharmacological and nonpharmacological strategies to improve sleep in individuals recovering from alcoholism have been studied. They are discussed in the sections 4.1 and 4.2.

## 4.1 Pharmacological Treatment

### 4.1.1 GABAergic Agents

BDZs have documented efficacy in the prevention or treatment of acute withdrawal symptoms such as seizures and DTs.<sup>[9,102]</sup> They are, however, not recommended for the treatment of alcohol-related sleep disturbances. They are cross-tolerant with alcohol and carry the risk of misuse or abuse themselves.<sup>[90]</sup> An early study showed that during 6 days after alcohol withdrawal using the BDZs chlordiazepoxide, REM sleep was initially suppressed, while SWS remained virtually eliminated.<sup>[38]</sup> A prominent reduction of EEG delta activity in non-REM sleep is a consistent finding with BDZs and analogues in healthy individuals, even after sleep deprivation.<sup>[103]</sup>

In alcohol-dependent rats, the GABA agonists muscimol and homotaurine reduced wakefulness and increased non-REM and REM sleep in the light period during the first day of alcohol withdrawal.<sup>[104]</sup> These effects were in contrast to those in animals that were not alcohol-dependent, in which no changes were seen. Whether the tonic stimulation of GABAergic neurotransmission can

improve disturbed sleep in abstinent patients remains to be established.

Activation of GABA<sub>A</sub> receptors with THIP and presynaptic GABA<sub>B</sub> receptors with GHB<sup>[105]</sup> promotes SWS and SWA in young healthy men.<sup>[68,86]</sup> However, the low therapeutic index and considerable abuse potential of GHB<sup>[106]</sup> may limit the clinical potential of this agent in the treatment of alcohol dependence.

Preliminary findings indicate that gabapentin, which may increase the concentration of GABA in the brain, may improve subjective sleep quality during early abstinence in alcohol-dependent patients.<sup>[107]</sup>

### 4.1.2 Serotonergic Agents

It is well established that the 5-HT<sub>2</sub> receptor antagonists ritanserin and seganserin increase the amount of SWS and enhance EEG SWA in healthy humans and animals.<sup>[71,87,108,109]</sup> In contrast, ritanserin failed to promote SWS during 4 weeks of abstinence in 10 patients with chronic alcoholism and dysthymia who had undergone BDZ treatment until 7 days prior to the study compared with 10 patients in the placebo group.<sup>[110]</sup> Nevertheless, total sleep time, the duration of non-REM sleep and sleep efficiency were enhanced, wakefulness reduced, and symptoms of depression and anxiety improved when compared with placebo. Moreover, a preliminary clinical study suggested that ritanserin may reduce alcohol craving and the rate of relapses in 5 recently abstinent alcohol-dependent individuals.<sup>[111]</sup> In a large multicentre trial, however, no enhanced benefit of this drug was found when it was used as an adjunctive medication to cognitive-behavioural therapy in 423 patients.<sup>[112]</sup>

Based on clinical observations in healthy individuals and those who abuse alcohol, 5-HT<sub>3</sub> antagonists have been suggested to hold promise for the treatment of alcohol dependence.<sup>[99,113]</sup> Compared with other serotonin receptor subclasses, 5-HT<sub>3</sub> receptors appear to play a minor role in sleep-wake regulation.<sup>[114,115]</sup> In accordance with this view, only slight and nonconsistent changes in sleep variables and nocturnal endocrine measures were found in 8 healthy men during 5 days of tropisetron



administration.<sup>[116]</sup> However, a recent study including a total of 321 patients (160 patients with late onset alcoholism and 161 patients with early onset alcoholism) has indicated that distinct subgroups of alcohol-dependent patients may respond differently to 5-HT<sub>3</sub> receptor inhibition. Specifically, the selective antagonist ondansetron improved drinking and abstinence compared with placebo in the patients with early onset alcoholism (who developed the disorder at age  $\leq 25$  years), whereas it was not superior to placebo in the patients with late onset alcoholism ( $>25$  years).<sup>[117]</sup> Whether the treatment affected sleep and whether the sleep effects differed between the diagnostic subgroups is unknown. Nevertheless, in view of a genetic heterogeneity between early and late onset alcoholism,<sup>[118]</sup> this study highlights the importance of pharmacogenetic approaches in the treatment of alcohol dependence.

#### 4.1.3 Other Medications

##### Melatonin

Alcohol inhibits nocturnal synthesis of melatonin,<sup>[119]</sup> and night-time serum levels of the pineal hormone may be reduced in alcohol-dependent patients during withdrawal.<sup>[120]</sup> Preliminary studies of controlled release melatonin administered to improve sleep quality in patients with major depression and schizophrenia revealed equivocal results and did not report sleep EEG data.<sup>[121,122]</sup> Whether exogenous melatonin can ameliorate sleep objectively and/or subjectively during alcohol recovery has not been studied.

##### Ethanol

It may be reasonable to assume that controlled low dose administration of ethanol may prevent withdrawal symptoms. Two recent articles, however, disagree on the usefulness of this approach in the pharmacological management of alcohol withdrawal.<sup>[9,10]</sup> In one early study, SWS improved to normal levels within 3 to 4 days after  $\approx 4$  days of alcohol withdrawal moderated with a decreasing low dose of ethanol.<sup>[38]</sup> In contrast, SWS remained virtually absent during 6 days after ethanol withdrawal supported with the BDZ chlordiazepoxide.

In another study, patients with low values of SWS after 2 to 3 weeks of abstinence (i.e. baseline) showed a larger SWS promotion with ethanol, yet a more rapid development of tolerance and a poorer treatment outcome after 2 months than patients with higher amounts of SWS at baseline.<sup>[38]</sup>

To our knowledge, these preliminary findings on the relationship between SWS and treatment outcome have not been replicated, and the efficacy and safety of low dose ethanol detoxification has not been evaluated in controlled clinical trials.

##### Antidepressants

Sedating antidepressants such as trazodone are commonly used during alcohol withdrawal, but their efficacy and safety have not been studied appropriately. Furthermore, selective serotonin reuptake inhibitors appear to be rather unsuitable as sleeping aids, and they have not been convincing in prevention of relapse in recovering alcohol-dependent patients.<sup>[99,100]</sup>

##### Treatments for Sleep Apnoea and Periodic Limb Movements

The connection between sleep disturbances and alcoholic relapse suggests that patients should be screened for the presence of sleep apnoea and periodic leg movements. The clinical treatment of these disorders has recently been reviewed elsewhere.<sup>[1,123-126]</sup>

#### 4.2 Nonpharmacological and Alternative Treatments

Effective nonpharmacological strategies for the treatment of insomnia include:

- relaxation techniques
- cognitive therapy
- stimulus control methods
- sleep restriction
- sleep hygiene education (i.e. avoidance of caffeinated beverages near bedtime, adherence to regular sleep-wake habits, exercising during the day).<sup>[127,128]</sup>

Although the benefits of these methods have not been studied specifically for alcohol-related sleep disturbances, they can and should be included in

any intervention to treat insomnia in alcohol-dependent patients.

The results of pilot studies in small samples of recovering alcohol-dependent individuals on the effects of bright light therapy,<sup>[129]</sup> dawn simulation<sup>[130]</sup> and homeopathy<sup>[131]</sup> warrant further investigation. Larger controlled studies are needed involving longer treatment and observation periods, follow-up assessment and outcome evaluations, and providing standard polysomnographic data to allow guidelines for therapeutic interventions to be designed.

## 5. Conclusions

Alcohol has a negative impact on sleep. Even after moderate drinking in individuals who are not alcohol-dependent, sleep in the second half of the night may be interrupted by frequent awakenings and perceived as superficial and shallow due to increased dreaming, sweating and headache. These effects may occur even when no alcohol has been detected in breath or plasma at bedtime. Moreover, the substance may induce, or exacerbate, sleep apnoea and nocturnal myoclonus.

Virtually every type of sleep problem occurs in alcohol-dependent patients. They typically have a long sleep latency, low sleep efficiency, short sleep duration and reduced amounts of SWS. Their sleep patterns are fragmented, and sleep architecture is severely disrupted. The percentage of REM sleep may be reduced or increased. Subjective sleep disturbances may contribute to continued drinking, and persistent alterations of sleep during withdrawal and abstinence may increase the risk of relapse into alcoholism.

There remain many open questions regarding the mechanisms of action of short and long term alcohol use on sleep and the sleep EEG, and the relationship between sleep, sleep abnormalities and alcoholism. For example, what adaptive changes underlie the initial promotion of SWS and SWA, which is followed by impaired sleep consolidation after short term alcohol consumption? How do zero or near-zero amounts of alcohol in the plasma affect sleep and the sleep EEG? What mechanisms

lead to suppression of SWS and disruption of normal non-REM/REM sleep cycles during long term alcohol ingestion? Can promotion of SWS and improvement of objective and subjective sleep quality prevent relapse into alcoholism? Are the sleep changes, which predict early relapse in alcohol-dependent patients, *per se* responsible for the poor therapeutic outcome, or do they reflect other underlying factors? Progress in the understanding of these and other questions<sup>[100]</sup> may lead to future therapies which improve sleep and reduce relapse in recovering patients.

## Acknowledgements

The authors have been supported by the Swiss National Science Foundation (823A-056616), the National Institute of Mental Health (MH38738), the UCSD Mental Health Clinical Research Center (MH30914), the Veterans Affairs Medical Research Service, the UCSD General Clinical Research Center (Michael Ziegler, MD, Director), and the UCSD Fellowship in Clinical Psychopharmacology and Psychobiology (Michael Irwin, MD, Director).

## References

- Gillin JC, Drummond SP. Medication and substance abuse. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 1176-95
- Brower KJ, Aldrich MS, Hall JM. Polysomnographic and subjective sleep predictors of alcoholic relapse. *Alcohol Clin Exp Res* 1998; 22 (8): 1864-71
- Gillin JC, Smith TL, Irwin M, et al. Increased pressure for rapid eye movement sleep at time of hospital admission predicts relapse in nondepressed patients with primary alcoholism at 3-month follow-up. *Arch Gen Psychiatry* 1994; 51 (3): 189-97
- Clark CP, Gillin JC, Golshan S, et al. Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression. *Biol Psychiatry* 1998; 43 (8): 601-7
- Drummond SP, Gillin JC, Smith TL, et al. The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse. *Alcohol Clin Exp Res* 1998; 22 (8): 1796-802
- Foster JH, Peters TJ. Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. *Alcohol Clin Exp Res* 1999; 23 (6): 1044-51
- Skoloda TE, Alterman AI, Gottheil E. Sleep quality reported by drinking and non-drinking alcoholics. In: Gottheil EL, editor. Addiction research and treatment: converging trends. New York: Pergamon Press, 1979: 102-12
- Vitiello MV. Sleep, alcohol and alcohol abuse. *Addiction Biol* 1997; 2: 151-8
- Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal [see comments]. *JAMA* 1997; 278 (2): 144-51

10. Lands WE. Alcohol, slow wave sleep, and the somatotrophic axis. *Alcohol* 1999; 18 (2-3): 109-22
11. Rechtschaffen A, Kales A, editors. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles (CA): UCLA Brain Information Service/Brain Research Institute, 1968
12. Preud'homme XA, Lanquart J-P, Mendlewicz J, et al. Characteristics of spontaneous sleep with varying NREMS episodes in healthy men: implication for delta activity homeostasis. *Sleep* 2000; 23 (2): 193-203
13. Borbély AA, Baumann F, Brandeis D, et al. Sleep deprivation: effect on sleep stages and EEG power density in man. *Electroencephalogr Clin Neurophysiol* 1981; 51 (5): 483-95
14. Borbély AA, Achermann P. Sleep homeostasis and models of sleep regulation. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 377-90
15. Borbély AA. A two process model of sleep regulation. *Hum Neurobiol* 1982; 1 (3): 195-204
16. Daan S, Beersma DG, Borbély AA. Timing of human sleep: recovery process gated by a circadian pacemaker. *Am J Physiol* 1984; 246 (2 Pt 2): R161-R83
17. Werth E, Dijk DJ, Achermann P, et al. Dynamics of the sleep EEG after an early evening nap: experimental data and simulations. *Am J Physiol* 1996; 271 (3 Pt 2): R501-R10
18. Aeschbach D, Borbély AA. All-night dynamics of the sleep EEG. *J Sleep Res* 1993; 2: 70-81
19. Dijk DJ, Hayes B, Czeisler CA. Dynamics of electroencephalographic sleep spindles and slow wave activity in men: effect of sleep deprivation. *Brain Res* 1993; 626 (1-2): 190-9
20. Gresham SC, Webb WB, Williams RL. Alcohol and caffeine: effect on inferred visual dreaming. *Science* 1963; 140: 1226-7
21. Yules RB, Freedman DX, Chandler KA. The effect of ethyl alcohol on man's electroencephalographic sleep cycle. *Electroencephalogr Clin Neurophysiol* 1966; 20 (2): 109-11
22. Knowles JB, Laverty SG, Kuechler HA. Effects of alcohol on REM sleep. *Q J Stud Alcohol* 1968; 29 (2): 342-9
23. Rundell OH, Lester BK, Griffiths WJ, et al. Alcohol and sleep in young adults. *Psychopharmacologia* 1972; 26 (3): 201-18
24. MacLean AW, Cairns J. Dose-response effects of ethanol on the sleep of young men. *J Stud Alcohol* 1982; 43 (5): 434-44
25. Williams DL, MacLean AW, Cairns J. Dose-response effects of ethanol on the sleep of young women. *J Stud Alcohol* 1983; 44 (3): 515-23
26. Madsen BW, Rossi L. Sleep and Michaelis-Menten elimination of ethanol. *Clin Pharmacol Ther* 1980; 27 (1): 114-9
27. Landolt HP, Roth C, Dijk DJ, et al. Late-afternoon ethanol intake affects nocturnal sleep and the sleep EEG in middle-aged men. *J Clin Psychopharmacol* 1996; 16 (6): 428-36
28. Thorpy MJ. Classification of sleep disorders. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 547-57
29. Vestal RE, McGuire EA, Tobin JD, et al. Aging and ethanol metabolism. *Clin Pharmacol Ther* 1977; 21 (3): 343-54
30. Pozzato G, Moretti M, Franzin F, et al. Ethanol metabolism and aging: the role of 'first pass metabolism' and gastric alcohol dehydrogenase activity. *J Gerontol A Biol Sci Med Sci* 1995; 50 (3): B135-B41
31. Dijk DJ, Brunner DP, Aeschbach D, et al. The effects of ethanol on human sleep EEG power spectra differ from those of benzodiazepine receptor agonists. *Neuropsychopharmacology* 1992; 7 (3): 225-32
32. Roehrs T, Beare D, Zorick F, et al. Sleepiness and ethanol effects on simulated driving. *Alcohol Clin Exp Res* 1994; 18 (1): 154-8
33. Dawson A, Lehr P, Bigby BG, et al. Effect of bedtime ethanol on total inspiratory resistance and respiratory drive in normal nonsnoring men. *Alcohol Clin Exp Res* 1993; 17 (2): 256-62
34. LeBon O, Verbanck P, Hoffmann G, et al. Sleep in detoxified alcoholics: impairment of most standard sleep parameters and increased risk for sleep apnea, but not for myoclonias – a controlled study. *J Stud Alcohol* 1997; 58 (1): 30-6
35. Aldrich MS, Shipley JE. Alcohol use and periodic limb movements of sleep. *Alcohol Clin Exp Res* 1993; 17 (1): 192-6
36. Benca RM, Obermeyer WH, Thisted RA, et al. Sleep and psychiatric disorders. A meta-analysis. *Arch Gen Psychiatry* 1992; 49 (8): 651-68
37. Mello NK, Mendelson JH. Behavioral studies of sleep patterns in alcoholics during intoxication and withdrawal. *J Pharmacol Exp Ther* 1970; 175 (1): 94-112
38. Allen RP, Wagman AM, Funderburk FR. Slow wave sleep changes: alcohol tolerance and treatment implications. *Adv Exp Med Biol* 1977; 85A: 629-40
39. Johnson LC, Burdick JA, Smith J. Sleep during alcohol intake and withdrawal in the chronic alcoholic. *Arch Gen Psychiatry* 1970; 22 (5): 406-18
40. Smith JW, Johnson LC, Burdick JA. Sleep, psychological and clinical changes during alcohol withdrawal in NAD-treated alcoholics. *Q J Stud Alcohol* 1971; 32 (4): 982-94
41. Allen RP, Wagman A, Faillace LA, et al. Electroencephalographic (EEG) sleep recovery following prolonged alcohol intoxication in alcoholics. *J Nerv Ment Dis* 1971; 153 (6): 424-33
42. Nakazawa Y, Yokoyama T, Koga Y, et al. Polysomnographic study of terminal sleep following delirium tremens. *Drug Alcohol Depend* 1981; 8 (2): 111-7
43. Kotorii T, Nakazawa Y, Yokoyama T, et al. Terminal sleep following delirium tremens in chronic alcoholics – polysomnographic and behavioral study. *Drug Alcohol Depend* 1982; 10 (2-3): 125-34
44. Wagman AM, Allen RP. Effects of alcohol ingestion and abstinence on slow wave sleep of alcoholics. *Adv Exp Med Biol* 1975; 59: 453-66
45. Gillin JC, Smith TL, Irwin M, et al. EEG sleep studies in 'pure' primary alcoholism during subacute withdrawal: relationships to normal controls, age, and other clinical variables. *Biol Psychiatry* 1990; 27 (5): 477-88
46. Brown SA, Inaba RK, Gillin JC, et al. Alcoholism and affective disorder: clinical course of depressive symptoms. *Am J Psychiatry* 1995; 152 (1): 45-52
47. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. *Arch Gen Psychiatry* 1972; 26 (1): 57-63
48. Cadoret R, Winokur G. Depression in alcoholism. *Ann N Y Acad Sci* 1974; 233: 34-9
49. Schuckit MA. The clinical implications of primary diagnostic groups among alcoholics. *Arch Gen Psychiatry* 1985; 42 (11): 1043-9
50. Moeller FG, Gillin JC, Irwin M, et al. A comparison of sleep EEGs in patients with primary major depression and major depression secondary to alcoholism. *J Affect Disord* 1993; 27 (1): 39-42
51. Clark CP, Gillin JC, Golshan S, et al. Polysomnography and depressive symptoms in primary alcoholics with and without a lifetime diagnosis of secondary depression and in patients with primary major depression. *J Affect Disord* 1999; 52 (1-3): 177-85
52. Williams HL, Rundell OJ. Altered sleep physiology in chronic alcoholics: reversal with abstinence. *Alcohol Clin Exp Res* 1981; 5 (2): 318-25

53. Eckardt MJ, File SE, Gessa GL, et al. Effects of moderate alcohol consumption on the central nervous system. *Alcohol Clin Exp Res* 1998; 22 (5): 998-1040
54. Little HJ. The contribution of electrophysiology to knowledge of the acute and chronic effects of ethanol. *Pharmacol Ther* 1999; 84 (3): 333-53
55. Borbély AA, Tobler I. Endogenous sleep-promoting substances and sleep regulation. *Physiol Rev* 1989; 69 (2): 605-70
56. Steriade M, McCormick DA, Sejnowski TJ. Thalamic oscillations in the sleeping and aroused brain. *Science* 1993; 262 (5134): 679-85
57. Benington JH, Heller HC. Restoration of brain energy metabolism as the function of sleep. *Prog Neurobiol* 1995; 45 (4): 347-60
58. McCormick DA, Bal T. Sleep and arousal: thalamocortical mechanisms. *Annu Rev Neurosci* 1997; 20: 185-215
59. Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. *J Biol Rhythms* 1997; 12 (6): 627-35
60. Zolotowski RK, Cabeza RdJ, Gillin JC. Biochemical pharmacology of sleep. In: Chokroverty S, editor. *Sleep disorders medicine: basic science, technical considerations and clinical aspects*. 2nd ed. Boston (MA): Butterworth-Heinemann, 1998: 63-94
61. Lancel M. Role of GABA<sub>A</sub> receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. *Sleep* 1999; 22 (1): 33-42
62. Landolt HP, Gillin JC. GABA<sub>A1a</sub> receptors: involvement in sleep regulation and potential of selective agonist in the treatment of insomnia. *CNS Drugs* 2000; 13 (3): 185-99
63. Sinton CM, McCarley RW. Neuroanatomical and neurophysiological aspects of sleep: basic science and clinical relevance. *Semin Clin Neuropsychiatry* 2000; 5 (1): 6-19
64. Borbély AA. Principles of sleep regulation: implications for the effect of hypnotics on sleep. In: Kales A, editor. *Pharmacology of sleep*. Berlin: Springer Verlag, 1995: 29-45
65. Dijk DJ, Roth C, Landolt HP, et al. Melatonin effect on daytime sleep in men: suppression of EEG low frequency activity and enhancement of spindle frequency activity. *Neurosci Lett* 1995; 201 (1): 13-6
66. Tenn CC, Niles LP. Central-type benzodiazepine receptors mediate the antidepressant effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism. *J Pharmacol Exp Ther* 1995; 274 (1): 84-9
67. Lancel M, Cronlein TA, Faulhaber J. Role of GABA<sub>A</sub> receptors in sleep regulation. Differential effects of muscimol and midazolam on sleep in rats. *Neuropsychopharmacology* 1996; 15 (1): 63-74
68. Faulhaber J, Steiger A, Lancel M. The GABA<sub>A</sub> agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. *Psychopharmacology (Berl)* 1997; 130 (3): 285-91
69. Lancel M, Faulhaber J, Deisz RA. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. *Br J Pharmacol* 1998; 123 (7): 1471-7
70. Seifritz E, Moore P, Trachsel L, et al. The 5-HT<sub>1A</sub> agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT<sub>2</sub> blockade. *Neurosci Lett* 1996; 209 (1): 41-4
71. Dijk DJ, Beersma DG, Daan S, et al. Effects of seganserin, a 5-HT<sub>2</sub> antagonist, and temazepam on human sleep stages and EEG power spectra. *Eur J Pharmacol* 1989; 171 (2-3): 207-18
72. Landolt HP, Meier V, Burgess HJ, et al. Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra. *Neuropsychopharmacology* 1999; 21 (3): 455-66
73. Suzdak PD, Schwartz RD, Skolnick P, et al. Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptosomes. *Proc Natl Acad Sci U S A* 1986; 83 (11): 4071-5
74. Aguayo LG. Ethanol potentiates the GABA<sub>A</sub>-activated Cl<sup>-</sup> current in mouse hippocampal and cortical neurons. *Eur J Pharmacol* 1990; 187 (1): 127-30
75. Minami K, Minami M, Harris RA. Inhibition of 5-hydroxytryptamine type 2A receptor-induced currents by n-alcohols and anesthetics. *J Pharmacol Exp Ther* 1997; 281 (3): 1136-43
76. Gervasoni D, Peyron C, Rampon C, et al. Role and origin of the GABAergic innervation of dorsal raphe serotonergic neurons. *J Neurosci* 2000; 20 (11): 4217-25
77. Benington JH, Kodali SK, Heller HC. Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation. *Brain Res* 1995; 692 (1-2): 79-85
78. Schwierin B, Borbély AA, Tobler I. Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. *Eur J Pharmacol* 1996; 300 (3): 163-71
79. Nagy LE, Diamond I, Casso DJ, et al. Ethanol increases extracellular adenosine by inhibiting adenosine uptake via the nucleoside transporter. *J Biol Chem* 1990; 265 (4): 1946-51
80. Krauss SW, Ghimikar RB, Diamond I, et al. Inhibition of adenosine uptake by ethanol is specific for one class of nucleoside transporters. *Mol Pharmacol* 1993; 44 (5): 1021-6
81. Landolt HP, Dijk DJ, Gaus SE, et al. Caffeine reduces low-frequency delta activity in the human sleep EEG. *Neuropsychopharmacology* 1995; 12 (3): 229-38
82. Landolt HP, Werth E, Borbély AA, et al. Caffeine intake (200 mg) in the morning affects human sleep and EEG power spectra at night. *Brain Res* 1995; 675 (1-2): 67-74
83. Diao L, Dunwiddie TV. Interactions between ethanol, endogenous adenosine and adenosine uptake in hippocampal brain slices. *J Pharmacol Exp Ther* 1996; 278 (2): 542-6
84. Krueger JM, Obal FJ, Fang J. Humoral regulation of physiological sleep: cytokines and GHRH. *J Sleep Res* 1999; 8 Suppl. 1: 53-9
85. VanCauter E, Copinschi G. Interactions between growth hormone secretion and sleep. In: Smith RG, Thorner MO, editors. *Human growth hormone: research and clinical practice*. Totowa (NJ): Humana Press, 2000: 261-83
86. VanCauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. *J Clin Invest* 1997; 100 (3): 745-53
87. Gronfier C, Luthringer R, Follenius M, et al. A quantitative evaluation of the relationships between growth hormone secretion and delta wave electroencephalographic activity during normal sleep and after enrichment in delta waves. *Sleep* 1996; 19 (10): 817-24
88. Prinz PN, Roehrs TA, Vitaliano PP, et al. Effect of alcohol on sleep and nighttime plasma growth hormone and cortisol concentrations. *J Clin Endocrinol Metab* 1980; 51 (4): 759-64
89. Chalmers RJ, Bennie EH, Johnson RH, et al. Growth hormone, prolactin, and corticosteroid responses to insulin hypoglycaemia in alcoholics. *BMJ* 1978; 1 (6115): 745-8
90. Meyer RE. Prospects for a rational pharmacotherapy of alcoholism. *J Clin Psychiatry* 1989; 50 (11): 403-12
91. Freund G, Ballinger WE. Loss of muscarinic and benzodiazepine neuroreceptors from hippocampus of alcohol abusers. *Alcohol* 1989; 6: 23-31
92. Freund G, Anderson KJ. Glutamate receptors in the frontal cortex of alcoholics. *Alcohol Clin Exp Res* 1996; 20 (7): 1165-72
93. Kaplan GB, Bharmal NH, Leite-Morris KA, et al. Role of adenosine A1 and A2A receptors in the alcohol withdrawal syndrome. *Alcohol* 1999; 19 (2): 157-62

94. Faingold C, Li Y, Evans MS. Decreased GABA and increased glutamate receptor-mediated activity on inferior colliculus neurons *in vitro* are associated with susceptibility to ethanol withdrawal seizures. *Brain Res* 2000; 868: 287-95
95. Volkow ND, Wang G-J, Fowler JS, et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. *Alcohol Clin Exp Res* 1996; 20 (9): 1594-8
96. Laine TPJ, Ahonen A, Tornainen P, et al. Dopamine transporters increase in human brain after alcohol withdrawal. *Mol Psychiatry* 1999; 4: 189-91
97. Balldin JJ, Berggren UC, Lindstedt G. Neuroendocrine evidence for reduced dopamine receptor sensitivity in alcoholism. *Alcohol Clin Exp Res* 1992; 16 (1): 71-4
98. Heinz A, Ragan P, Jones DW, et al. Reduced central serotonin transporters in alcoholism. *Am J Psychiatry* 1998; 155 (11): 1544-9
99. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. *Psychopharmacology (Berl)* 2000; 149: 327-44
100. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. *Alcohol Alcohol* 2000; 35 (6): 537-47
101. Snyder S, Karacan I, Salis PJ. Effects of disulfiram on the sleep of chronic alcoholics. *Curr Alcohol* 1981; 8: 159-66
102. Thompson WL. Management of alcohol withdrawal syndromes. *Arch Intern Med* 1978; 138 (2): 278-83
103. Landolt HP, Finelli LA, Roth C, et al. Zolpidem and sleep deprivation: different effect on EEG power spectra. *J Sleep Res* 2000; 9 (2): 175-83
104. Rouhani S, Dall'Ava-Santucci J, Bajenaru O, et al. Effects of muscimol or homotaurine on sleep-wake states in alcohol-dependent rats during withdrawal. *Pharmacol Biochem Behav* 1998; 59 (4): 955-60
105. Emri Z, Antal K, Crunelli V. Gamma-hydroxybutyric acid decreases thalamic sensory excitatory postsynaptic potentials by an action on presynaptic GABA<sub>B</sub> receptors. *Neurosci Lett* 1996; 216 (2): 121-4
106. Galloway GP, Frederick SL, Staggers Jr FE, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. *Addiction* 1997; 92 (1): 89-96
107. Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence [letter]. *Am J Psychiatry* 2000; 157 (1): 151
108. Idzikowski C, Mills FJ, Glennard R. 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. *Brain Res* 1986; 378 (1): 164-8
109. Borbély AA, Trachsel L, Tobler I. Effect of ritanserin on sleep stages and sleep EEG in the rat. *Eur J Pharmacol* 1988; 156 (2): 275-8
110. Monti JM, Alterwain P, Estevez F, et al. The effects of ritanserin on mood and sleep in abstinent alcoholic patients. *Sleep* 1993; 16 (7): 647-54
111. Monti JM, Alterwain P. Ritanserin decreases alcohol intake in chronic alcoholics [letter]. *Lancet* 1991; 337 (8732): 60
112. Johnson BA, Jasinski DR, Galloway GP, et al. Ritanserin in the treatment of alcohol dependence – a multi-center clinical trial. Ritanserin Study Group. *Psychopharmacology (Berl)* 1996; 128 (2): 206-15
113. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. *Biol Psychiatry* 1994; 36 (5): 326-37
114. Adrien J. Are other 5-HT receptors besides 5-HT<sub>1A</sub> and 5-HT<sub>2</sub> involved in the regulation of sleep and wakefulness. *J Sleep Res* 1992; 1: 176-7
115. Adrien J. The serotonergic system and sleep-wakefulness regulation. In: Kales A, editor. *The pharmacology of sleep*. Berlin: Springer Verlag, 1995: 91-116
116. Rothe B, Guldner J, Hohlfeldt E, et al. Effects of 5HT<sub>3</sub> receptor antagonism by tropisetron on the sleep EEG and on nocturnal hormone secretion. *Neuropsychopharmacology* 1994; 11 (2): 101-6
117. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. *JAMA* 2000; 284 (8): 963-71
118. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. *Science* 1987; 236: 410-6
119. Ekman AC, Leppaluoto J, Huttunen P, et al. Ethanol inhibits melatonin secretion in healthy volunteers in a dose-dependent randomized double blind cross-over study. *J Clin Endocrinol Metab* 1993; 77 (3): 780-3
120. Schmitz MM, Sepandj A, Pichler PM, et al. Disrupted melatonin-secretion during alcohol withdrawal. *Prog Neuropsychopharmacol Biol Psychiatry* 1996; 20 (6): 983-95
121. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. *Am J Psychiatry* 1998; 155 (8): 1119-21
122. Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia. *J Clin Psychiatry* 2000; 61 (5): 373-7
123. White DP. Central sleep apnea. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 827-39
124. Sanders MH. Medical therapy for obstructive sleep apnea-hypopnea syndrome. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 879-93
125. Kryger MH. Management of obstructive sleep apnea-hypopnea syndrome: overview. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 940-54
126. Montplaisir J, Nicolas A, Godbout R, et al. Restless legs syndrome and periodic limb movement disorder. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. 3rd ed. Philadelphia (PA): WB Saunders, 2000: 742-52
127. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. *Am J Psychiatry* 1994; 151 (8): 1172-80
128. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial [see comments]. *JAMA* 1999; 281 (11): 991-9
129. Schmitz M, Frey R, Pichler P, et al. Sleep quality during alcohol withdrawal with bright light therapy. *Prog Neuropsychopharmacol Biol Psychiatry* 1997; 21 (6): 965-77
130. Avery DH, Bolte MA, Ries R. Dawn simulation treatment of abstinent alcoholics with winter depression. *J Clin Psychiatry* 1998; 59 (1): 36-42
131. Rogers J. Homeopathy and the treatment of alcohol-related problems. *Complement Ther Nurs Midwifery* 1997; 3 (1): 21-8

---

Correspondence and offprints: Dr J. Christian Gillin, University of California, San Diego, Mental Health Clinical Research Center, Psychiatry Service (116-A), VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA.  
E-mail: jgillin@ucsd.edu